Can Diabetes Drugs Help Prevent Knee Surgery? What New Research Shows

A large study from Shanghai tracked 1,807 patients with both knee osteoarthritis and type 2 diabetes. Researchers compared 233 people taking GLP-1 receptor agonists—drugs like liraglutide and semaglutide originally designed to control blood sugar—against 1,574 people not using these medications. The finding: patients on GLP-1 drugs had significantly fewer knee surgeries over the study period. This is the biggest real-world look so far at how these medications affect surgery rates in people with both conditions.

The interest in using diabetes drugs for joint problems has grown as doctors look for new ways to manage osteoarthritis, the wear-and-tear breakdown of cartilage in joints. With surgery waiting times stretching longer and osteoarthritis becoming more common, researchers want to know if existing medications might help avoid the operating room.

But the picture emerging from recent studies is more complicated than that. While GLP-1 drugs may reduce the need for surgery, they don't seem to do what osteoarthritis patients most want: reduce knee pain.

Surgery Prevention Doesn't Equal Pain Relief

Here's where things get puzzling. The Shanghai study found that GLP-1 users needed fewer surgeries. Yet when researchers looked at pain specifically, a controlled trial of liraglutide in overweight patients with osteoarthritis showed no meaningful pain reduction compared to a placebo after one year.

This gap tells us something important about how osteoarthritis works. The decision to have knee replacement surgery isn't just about pain. Doctors consider how damaged the joint structure has become, how well the patient can move, and their overall quality of life. So the fewer surgeries GLP-1 users had could come from several different reasons: perhaps the drugs helped control blood sugar, which slowed cartilage damage. Or maybe better glucose control meant patients were healthier candidates for surgery and didn't need it as urgently. Or the weight loss from these medications could have reduced the mechanical stress on knees.

The point is: we don't know yet which mechanism (or combination of them) is actually at work.

Getting Patients Ready for Surgery

Researchers at Yale found another potential use for these drugs. They studied patients with type 2 diabetes who were about to have knee replacement surgery. Those who took semaglutide for three months before surgery had better recovery outcomes than those who didn't. This fits a broader trend in orthopedic medicine called "prehabilitation"—getting patients medically optimized before elective procedures to help them heal faster and better.

The practical advantage is real: three months roughly matches the waiting time many patients already face before knee surgery, so this approach wouldn't delay treatment.

But cost is becoming a serious concern. GLP-1 drugs typically cost over $1,000 per month, and that's stretching healthcare budgets. Health economists are asking: if we use these expensive medications to help prevent knee surgery, do we actually save money overall? The answer depends on complex calculations. On one side, you have the medication cost. On the other, you have what you might save by avoiding a $30,000 to $50,000 knee replacement procedure. But the full picture is messier because these drugs also help with heart health and weight loss, benefits that matter beyond just the knee.

Weight Loss May Be the Key

Current guidelines for treating osteoarthritis strongly emphasize weight loss for overweight and obese patients. The science is clear: every kilogram of weight you lose reduces the force pressing down on your knee joints by roughly four kilograms when you walk or stand.

GLP-1 drugs typically help people lose 10 to 15 percent of their body weight by suppressing appetite and slowing how fast food leaves the stomach. This weight loss mechanism might be all that's needed to explain why patients in the Shanghai study needed fewer surgeries—not because these drugs directly heal cartilage or reduce inflammation in the joint itself.

This pattern isn't entirely new in medicine. Years ago, statins were developed to lower cholesterol, but researchers later found they reduced heart attacks and strokes through broader cardiovascular benefits. Over time, statins found uses in preventing other conditions, from stroke to potentially even cancer. The question now is whether GLP-1 agonists will follow a similar path or stay mainly as weight-loss helpers for osteoarthritis patients.

What This Could Mean for Patients and Doctors

For doctors treating patients who have both diabetes and osteoarthritis, these findings offer something useful: evidence that GLP-1 drugs might reduce the need for surgery. But this is different from reducing pain, and that distinction matters. Many patients hope for relief from their symptoms right now, not just a lower chance of needing surgery down the road. Doctors will need to be clear about what these drugs can and can't do.

The Yale approach—giving patients three months of semaglutide before surgery—offers a concrete way doctors could use this information. It fits the existing surgical schedule and has shown benefits.

Still, the cost question isn't resolved. Healthcare systems need better answers about whether the savings from avoided surgeries outweigh the high cost of the medication. The math gets somewhat easier when you factor in the heart and metabolic benefits these drugs provide, but it still requires sophisticated analysis to sort out.

The current research leaves important questions unanswered. The Shanghai study showed a pattern but couldn't prove that the GLP-1 drugs caused fewer surgeries—only that the two things happened together. To know for sure, researchers would need long-term randomized trials comparing these drugs directly to placebos, watching for surgery rates over years. Those studies are difficult and expensive, but they would give doctors stronger evidence.

There's also mystery about the mechanism. Are GLP-1 receptors—the proteins these drugs attach to—present in joint tissue and actively reducing inflammation there? Or is the benefit purely from weight loss and improved blood sugar control? The answer matters because it would help doctors decide which patients benefit most and what dose to use.

Additionally, most research has focused on the knee in diabetic patients. Hip osteoarthritis and non-diabetic people with knee arthritis may behave differently. The forces on a hip joint differ from those on a knee, and the metabolic benefits of these drugs may not apply as much to non-diabetic patients.

What we're seeing is a broader shift in how doctors manage chronic disease. Rather than treating diabetes, osteoarthritis, and obesity as separate problems, they're starting to see them as connected and treatable with shared tools. The Shanghai findings add a useful piece to this puzzle, even though they also show us how much remains to be learned about this emerging approach.